Kevin Foley, MD, a board-certified neurosurgeon, will present DiscGenics' recent findings in a lecture titled "Initial In Vivo Efficacy of a Novel Injectable Cellular Therapy for Degenerative Disc Disease" at the annual Lumbar Research Society meeting.
The study, primarily authored by Dr. Foley, examines the efficacy and safety of Injectable Discogenic Cell Therapy.
Dr. Foley holds several professional appointments including director of complex spine surgery at Semmes-Murphey Neurologic and Spine Institute and professor of neurosurgery at the University of Tennessee Health Science Center, both in Memphis.
DiscGenics is a spine therapeutics company focused on stem cell and tissue engineering treatments for degenerative disc disease.
More Articles on Spine:
Mercy Medical Center – Des Moines Earns Blue Distinction
10 Statistics on Reoperation After Spine Surgery for Disc Herniation
Infection Rate Associated With Irradiated Allograft Bone
The study, primarily authored by Dr. Foley, examines the efficacy and safety of Injectable Discogenic Cell Therapy.
Dr. Foley holds several professional appointments including director of complex spine surgery at Semmes-Murphey Neurologic and Spine Institute and professor of neurosurgery at the University of Tennessee Health Science Center, both in Memphis.
DiscGenics is a spine therapeutics company focused on stem cell and tissue engineering treatments for degenerative disc disease.
More Articles on Spine:
Mercy Medical Center – Des Moines Earns Blue Distinction
10 Statistics on Reoperation After Spine Surgery for Disc Herniation
Infection Rate Associated With Irradiated Allograft Bone